Amgen (BSP:AMGN34) Research & Development : R$23,758 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Amgen Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Amgen's Research & Development for the three months ended in Dec. 2023 was R$7,516 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was R$23,758 Mil.

Amgen Research & Development Historical Data

The historical data trend for Amgen's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Research & Development Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

16,894.12

21,643.75

27,250.96

23,258.10

23,440.64

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Research & Development	Get a 7-Day Free Trial															6,944.91	5,510.70	5,402.17	5,328.86	7,516.29

Amgen Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$23,758 Mil.

Amgen (BSP:AMGN34) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Amgen Research & Development Related Terms

Thank you for viewing the detailed overview of Amgen's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (BSP:AMGN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BSP:AMGN34) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (BSP:AMGN34) Headlines

No Headlines